Hepatitis B and C Therapeutics Market Expected to Reach $17.02 Billion by 2024, Driven by Advances in Treatment and Screening Policies The Hepatitis B and C therapeutics market is projected to hit $17.02 billion by 2024, fueled by innovations in treatment and national screening strategies that enhance global healthcare.

Hepatitis B and C Therapeutics Market Expected to Reach $17.02 Billion by 2024, Driven by Advances in Treatment and Screening Policies #USA #Austin #Hepatitis_B #Hepatitis_C #Antivirals

AbbVie's Mavyret Gains FDA Approval for Acute Hepatitis C Treatment AbbVie has received FDA approval for Mavyret, the first and only treatment for acute Hepatitis C patients, allowing immediate intervention upon diagnosis.

AbbVie's Mavyret Gains FDA Approval for Acute Hepatitis C Treatment #United_States #AbbVie #MAVYRET #Hepatitis_C #North_Chicago,_Illinois

AbbVie's MAVYRET® Gains FDA Approval for Acute Hepatitis C Treatment AbbVie’s MAVYRET® becomes the first eight-week treatment for acute hepatitis C, paving the way for better patient outcomes and disease management.

AbbVie's MAVYRET® Gains FDA Approval for Acute Hepatitis C Treatment #United_States #AbbVie #North_Chicago #MAVYRET #Hepatitis_C